title: Cardiovascular disease in patients with spondyloarthropathies.
abstract: Spondyloarthropathies are associated with a greater cardiovascular risk than expected based on the cardiac lesions known to occur in these diseases. The prevalence of several conventional risk factors is high in spondyloarthropathy patients, and chronic inflammation also contributes to premature plaque formation. In addition, susceptibility genes for spondyloarthropathies may be associated with an increased risk of cardiovascular disease. Finally, several drugs used to treat spondyloarthropathies may contribute to the occurrence of cardiovascular events. A careful evaluation of the cardiovascular risk profile is a key component of the management of patients with spondyloarthropathies.
authors.affiliation: Cardiology Department, Clermont Tonnerre Armed Forces Teaching Hospital, BP 41, 29240 Brest Armées, France. ulric.vinsonneau@wanadoo.fr
authors.forename: Ulric
authors.initials: U
authors.lastname: Vinsonneau
authors.forename: Aurore
authors.initials: A
authors.lastname: Brondex
authors.forename: Jacques
authors.initials: J
authors.lastname: Mansourati
authors.forename: Alain
authors.initials: A
authors.lastname: Saraux
authors.forename: Jean Christophe
authors.initials: JC
authors.lastname: Cornily
authors.forename: Florence
authors.initials: F
authors.lastname: Arlès
authors.forename: Patrick
authors.initials: P
authors.lastname: Godon
authors.forename: Gilles
authors.initials: G
authors.lastname: Quiniou
mesh_terms: D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use; D050197:Atherosclerosis / Q000503:physiopathology; D054537:Atrioventricular Block / Q000453:epidemiology / Q000235:genetics; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D015897:Comorbidity; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D015796:HLA-B27 Antigen / Q000235:genetics; D006329:Heart Conduction System / Q000503:physiopathology; D006349:Heart Valve Diseases / Q000453:epidemiology; D006801:Humans; D007783:Lactones / Q000494:pharmacology / Q000627:therapeutic use; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology; D025242:Spondylarthropathies / Q000188:drug therapy / Q000453:epidemiology* / Q000235:genetics; D013450:Sulfones / Q000494:pharmacology / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D018501:Antirheumatic Agents; D052246:Cyclooxygenase 2 Inhibitors; D015796:HLA-B27 Antigen; D007783:Lactones; D013450:Sulfones; D014409:Tumor Necrosis Factor-alpha; C116926:rofecoxib